Some gene mutations have been reported to be enriched at relapse of B-ALL, such as the histone acetyltransferase gene CREBBP, the histone methyltransferase gene SETD2, and the steroid receptor gene NR3C1 and NR3C2 [77]. This evidence concerns the gene PRDM9 and precursor B-cell acute lymphoblastic leukemia.